Introduction
============

Spontaneous miscarriage (SM) is a major cause of pregnancy failure. It is estimated that \~10-15% of all clinically recognized pregnancies terminate in SM ([@b1-mmr-22-02-1269],[@b2-mmr-22-02-1269]). In addition, \>50% of all SMs have chromosomal abnormalities (CAs) ([@b3-mmr-22-02-1269]--[@b5-mmr-22-02-1269]), including mosaicism, structural abnormalities and numerical chromosomal defects, such as trisomy, monosomy, polyploidy and monosomy X ([@b6-mmr-22-02-1269],[@b7-mmr-22-02-1269]). Furthermore, SM increases the risk of pregnancy loss and complications. Therefore, analysis of CAs in aborted tissues would provide insight into the etiology of pregnancy termination, as well as improved management of subsequent pregnancies in patients with SM ([@b8-mmr-22-02-1269],[@b9-mmr-22-02-1269]). Previous studies suggested that patient follow-up is more cost-effective when CA analyses are performed in patients who had experienced miscarriage ([@b10-mmr-22-02-1269],[@b11-mmr-22-02-1269]).

Conventional methods used to detect CAs and determine the cause of pregnancy loss include karyotyping, fluorescence in situ hybridization, quantitative fluorescent-PCR (QF-PCR) and multiplex ligation-dependent probe amplification. However, these methods have inherent limitations ([@b10-mmr-22-02-1269],[@b12-mmr-22-02-1269]). Following the rapid development of molecular biology technologies, array comparative genomic hybridization (CGH) and single nucleotide polymorphism (SNP) microarray ([@b13-mmr-22-02-1269],[@b14-mmr-22-02-1269]) have become the standard methods used to investigate possible chromosomal causes of miscarriage because of their ability to analyze the whole genome at high resolution. However, microarray assays have numerous limitations such as high cost, low throughput and requirement of a large amount of high-quality DNA. With the development of next-generation sequencing (NGS) and reduced sequencing costs, low-coverage NGS assays have been widely used for noninvasive pre-natal testing in China, which is also gradually expanding to the detection of CAs in SM ([@b1-mmr-22-02-1269],[@b9-mmr-22-02-1269],[@b15-mmr-22-02-1269],[@b16-mmr-22-02-1269]).

The aim of the present study was to develop a method based on low-coverage NGS to detect CAs in SM through a retrospective, case-controlled approach. The clinical performance of the developed method was then assessed in a prospective study. The performance of copy number variant (CNV) analysis based on low-coverage NGS technology is dependent on the sequencing coverage ([@b15-mmr-22-02-1269],[@b17-mmr-22-02-1269]). Increasing the coverage may increase the sensitivity of the CNV analysis method, while simultaneously increase the sequencing cost ([@b17-mmr-22-02-1269]). The present study used low-coverage NGS CNV analysis, which yielded \>3.5 million sequencing reads with CNVs \>1 Mb in length. Overall, the sequencing coverage was \~0.13X, with an average fragment length \~110 bp.

Materials and methods
=====================

### Study design

In total, 1,401 patients with SM were enrolled in the present study and divided into two groups. Group I included 437 samples previously validated by array CGH. Samples in group I were used to establish a method to detect CAs by semiconductor sequencing, using a retrospective, case-controlled study design. Group II, which lacked verified results, comprised 964 samples tested for clinical significance via a prospective design. Finally, CNVs with clear clinical significance in group II were verified by array CGH. The CNV-positive and euploid samples were subjected to short tandem repeat (STR) profiling to identify polyploidies.

### Samples and clinical materials

All samples were obtained under Institutional Review Board approved protocols with informed consent from all participants for research use at Nanfang Hospital, Southern Medical University (approval no. NFEC-2017-050). In total, 437 SM samples within 20 weeks of gestation with array CGH results, and 964 SM samples within 20 weeks of gestation but without array CGH results, were collected between August 2017 and February 2018. The maternal age range was 18--47 years, with a mean of 30 years. Gestational age ranged from 5 to 20 weeks, with a mean of 9 weeks and 2 days. Following collection, SM samples (chorionic or dermal tissue of SM) were rinsed three times in PBS and then stored in 15 ml centrifuge tubes (Corning Inc.) at −20°C until use.

### DNA extraction and fragmentation

Genomic DNA was extracted from SM samples using the DNEasy Blood and Tissue kit (Qiagen, GmbH) following the manufacturer\'s instructions, and stored at −80°C until use. DNA quality was evaluated using a NanoDrop™ spectrophotometer (Thermo Fisher Scientific, Inc.). Genomic DNA was sheared using the M220 instrument (Covaris) and DNA fragments 150--200 bp in length were purified using Agencourt AMPure XP beads (Beckman Coulter, Inc.), quantified using the Qubit^®^ 3.0 fluorometer (Thermo Fisher Scientific, Inc.), and stored at −80°C until use.

### DNA library construction and sequencing

Fragmented DNA samples served as input DNA to construct a DNA library for sequencing, using an Ion Plus Fragment Library kit (Thermo Fisher Scientific, Inc.). Agencourt AMPure XP beads (Beckman Coulter, Inc.) were used for purification during library construction. The DNA libraries were quantified using Qubit^®^ 3.0 (Thermo Fisher Scientific, Inc.) and their size distributions were verified using the Agilent High Sensitivity DNA kit on a 2100 Bioanalyzer (Agilent Technologies, Inc.). In total, 15 libraries were pooled and amplified by emulsion PCR using the Ion OneTouch™ 2 system (Thermo Fisher Scientific, Inc.). Template-positive ion sphere particles were enriched using the Ion OneTouch™ ES instrument (Thermo Fisher Scientific, Inc.). The ion sphere particles were immediately loaded onto the ion semiconductor chip, which was placed in an Ion Proton instrument (Thermo Fisher Scientific, Inc.) for sequencing, according to the manufacturer\'s instructions (300-cycle workflow).

### Data analysis

In total, \~5 million raw reads were obtained per sample. The mean length of sequencing reads was \~150 bp. The raw data were aligned to The National Center for Biotechnology Information GRCh37 human reference genome (<https://ftp.ncbi.nlm.nih.gov/genomes/refseq/vertebrate_mammalian/Homo_sapiens/all_assembly_versions>), and duplicates were identified using the Ion Torrent Server V5.4.11 (Torrent Mapping Alignment Program; Thermo Fisher Scientific, Inc.). Reads that mapped to multiple locations, had duplicate PCR products, or had a mapping quality score \<30 were discarded from analysis. Overall, \~75% (3.5 million) of the total reads were unique reads, which were retained. The genome was then partitioned into 50-kb non-overlapping bins, and raw counts were obtained for each bin. After binning, regions with high variability or low 'mappability' were excluded. To normalize the raw bin count, GC biases were corrected using Loess regression and principal component analysis (PCA) to remove higher-order artefacts, then divided by the total autosomal sequence length count to obtain genomic representation (GR) values ([@b18-mmr-22-02-1269]). The normalization process was based on previously reported studies ([@b19-mmr-22-02-1269],[@b20-mmr-22-02-1269]) and was as follows: i) Calibrate clean data to 10 million reads and normalize the read counts in each bin; ii) organize the normalized read counts and the baseline from 200 normal samples (in-house database) into a matrix and carry out PCA; iii) construct linear model by the top 20% principal components and normalized reads count; and iv) changing the residual error to reduce the effect of the data variance on the GR value of the test sample.

The GR values of normal samples were determined using a reference set, which was obtained from 200 healthy men (46, XY) and women (46, XX) (in-house database). To detect microdeletion and microduplication syndromes, the GR value of the test samples was divided by that of the reference set and the ratio was normalized to that of 10 million reads. The circular binary segmentation algorithm of the DNAcopy package in R (version 1.36.0; R Development Core Team) was used to distinguish copy number regions. The z score of each region was calculated using the formula: Z score = (region representation - median population)/MAD population, where region representation corresponds to the GRs of different copy number regions, the median population is the median region representation of all samples, and MAD population is the median absolute deviation of region representations within the reference set. A negative result was defined as a z score \<10 and a positive result as a z score ≥10.

### Array CGH validation

High-quality (A260/A280 ratio, 1.8:2.0; A260/A230 ratio, \>1.0) DNA was labeled and hybridized to the SurePrint G3 Human CGH Microarray 8×60K, consisting of 60,000 oligonucleotides. The whole genome was assayed at a backbone resolution of 200 kb. Slides were then scanned using the Agilent SureScan Microarray scanner. The images were analyzed using Agilent Genomic Workbench V7.0 (all from Agilent Technologies, Inc.).

### STR profiling validation by QF-PCR

First, 10--50 ng genomic DNA was amplified using QF-PCR using a thermal cycler. The thermocycling conditions were: 95°C for 5 min, 95°C for 30 sec, followed by 35 cycles at 58°C for 40 sec, 72°C for 50 sec, and finally 10 min at 72°C in a reaction volume of 25 µl. The resulting PCR products were subjected to capillary electrophoretic separation using the ABI3500 Genetic Analyzer (Applied Biosystems; Thermo Fisher Scientific, Inc.). Finally, the data were analyzed using GeneMapper^®^ Analysis V4.1 software (Applied Biosystems; Thermo Fisher Scientific; Inc.).

Results
=======

### Method development for the retrospective study

In the retrospective study, a method was developed based on low-coverage NGS to detect CAs in 437 abortion samples. The results obtained using this method presented high concordance with the array CGH results. In total, \>1 Mb CNV sequences were detected, and 3.5 million unique sequencing reads were obtained, at a lower cost. Of the 437 samples, 272 (62.2%) had abnormal chromosome numbers, including 195 (44.6%) aneuploidies, of which 156 (80.0%) were trisomies and 34 (17.4%) monosomies. In total, 68 (15.6%) samples were CNVs (size range, 204 kb-147 Mb), among which 56 were \>1 Mb and 12 were 0.2--1 Mb in length. In addition, 9 (2.0%) samples were mosaicisms, including five (46, XX/45, X) cases; one (46, XX/47, XX, +21) case, 46, XX/47, XX, +7 (with 50 Mb loss), one (47, XXY/46, XY) case and one (46, XY/47, XY, +8) case. There were 165 (37.8%) euploidy cases ([Fig. 1](#f1-mmr-22-02-1269){ref-type="fig"}). Furthermore, the most common CA detected among the SM samples was trisomy. In addition, four double aneusomies \[(48, XY, +12, +15); (48, XY, +9, +22); (48, XX, +3, +5); (48, XX, +8, +10)\] and one case of multiple aneusomy (49, XX, +13, +14, +21) were detected. [Table I](#tI-mmr-22-02-1269){ref-type="table"} summarizes the diagnostic performance of the present method for detecting CAs in SM.

All semiconductor sequencing platform (SSP) results agreed with those of array CGH, except for six CNVs \<1 Mb, which did not present CAs according to the SSP results. We searched for the 12 CNVs 0.2--1 Mb in size detected by array CGH within the Database of Genomic Variants (<http://dgv.tcag.ca/dgv/app/home>), DECIPHER database (<https://decipher.sanger.ac.uk/index>), and International Standard Cytogenomic Array database (<http://dbsearch.clinicalgenome.org/search>). All CNVs were found to be variants of uncertain significance (VOUS, referred to as CNV without further sub-classification).

### Prospective study

For the prospective study, abortion samples were obtained from 964 patients with SM. Using the present NGS method, 561 (58.2%) abnormal samples were detected, including 341 (35.4%) aneuploidies, 195 (20.2%) CNVs, 25 (2.6%) mosaicisms, and 403 (41.8%) euploidies ([Fig. 1](#f1-mmr-22-02-1269){ref-type="fig"}). Of the 341 aneuploid samples, T16 was the most common abnormality, followed by T22, T15, T21 and T13. Aneuploidy of chromosomes 1 and 19 was not seen (data not shown). However, one tetrasomy of chromosome 21 was observed using the NGS method and validated by STR profiling with QF-PCR ([Fig. 2](#f2-mmr-22-02-1269){ref-type="fig"}).

Among the 195 CNV cases (size range, 200 kb-96.75 Mb), 64 were \>1 Mb and 131 were \<1 Mb. Overall, 192 were not associated with any pathology, thus classified as VOUS. The remaining three CNVs comprised a contiguous gene deletion at 4p16.3-p15.33 (9.25 Mb) associated with Wolf-Hirschhorn syndrome (WHS), a microdeletion in chromosome 22q11.21 (1.35 Mb) associated with DiGeorge syndrome (DGS), and a loss-of-function gene located at 15q11.2-q13.1 (5.56 Mb) associated with both Prader-Willi (PW) and Angelman syndrome (AS). These three CNVs were pathogenic and confirmed by array CGH ([Fig. 3](#f3-mmr-22-02-1269){ref-type="fig"}).

Polyploidy is often observed in SM ([@b21-mmr-22-02-1269]). Since both array CGH and SSPs have a limited ability to detect polyploidies ([@b17-mmr-22-02-1269]), STR profiling using QF-PCR was performed in all samples to identify polyploidies. Overall, nine polyploidies were detected in female euploidy and sex chromosomal abnormalities, including five cases of (69, XXY) triploidy, two cases of (69, XXX) triploidy, one case of (69, XYY) triploidy and one of (92, XXXX) tetraploidy ([Fig. 4](#f4-mmr-22-02-1269){ref-type="fig"}). These were determined as (47, XXY), (46, XX), (47, XYY) and (46, XX), respectively, using the CNV analysis method based on low-coverage NGS and array CGH (data not shown).

Distribution of CAs among all samples. The 1,401 abortion samples carrying a CA comprised 536 (38.3%) aneuploidies, 263 (18.8%) CNVs, 34 (2.4%) mosaicisms and 568 (40.5%) euploidies ([Fig. 1](#f1-mmr-22-02-1269){ref-type="fig"}). The most common aneuploidies were T16 (n=101), (45, X) (n=81), T22 (n=66), T15 (n=36), T21 (n=29) and T13 (n=34) (data not shown). Furthermore, two monosomy 21 cases, 27 double aneusomies, two multiple aneusomies, and one tetrasomy 21 case were found.

Discussion
==========

DNA sequencing is widely used in medical research, and many biological problems can only be solved by sequencing technologies ([@b22-mmr-22-02-1269]). Due to its simplicity and rapidity, as well as its high throughput and resolution, NGS also has numerous applications in the clinical setting. For instance, NGS is considered to have clinical utility for the prevention of infectious diseases, noninvasive prenatal diagnosis, identification and diagnosis of genetic disorders, early diagnosis and treatment of cancer and pre-implantation ([@b23-mmr-22-02-1269]--[@b26-mmr-22-02-1269]). In the present study, a novel NGS method was developed for the detection of CAs in SM samples using an SSP, which could reliably and accurately diagnose genetic anomalies commonly associated with CAs. The results suggested that the performance of the present method was equivalent to that of array-based techniques.

Over the last 10 years, array-based methods, such as array CGH and SNP microarray, have become the gold standard for detection of aneuploidies, microdeletions and duplications, allowing high-resolution (0.1 Mb) chromosomal analysis ([@b27-mmr-22-02-1269]). However, array-based methods require large amounts of high-quality DNA and are too expensive for clinical testing of CAs. Compared with these technologies, NGS possesses clear advantages, including a lower requirement for nucleic acids, lower cost and high-throughput capability. More importantly, NGS technology can identify poorly represented DNA sequences missed by array-based methods. Advances in NGS technology have led to its application in CNV analysis. Several comparative studies demonstrated that NGS-based methods were a viable alternative technology to karyotyping and arrays for CA detection ([@b1-mmr-22-02-1269],[@b12-mmr-22-02-1269],[@b15-mmr-22-02-1269],[@b28-mmr-22-02-1269],[@b29-mmr-22-02-1269]). Previous prospective studies also suggested that NGS-based approaches are sensitive, reliable and accurate when detecting CAs in either SM or pre-natal samples ([@b27-mmr-22-02-1269],[@b30-mmr-22-02-1269]).

Chromosomal abnormalities are the main genetic causes for SM ([@b3-mmr-22-02-1269],[@b4-mmr-22-02-1269]). Aneuploidies, polyploidies and CNVs are the most common type of chromosomal abnormalities ([@b6-mmr-22-02-1269],[@b7-mmr-22-02-1269]). The resolution for CNVs detection is different in pre-natal diagnosis and spontaneous abortion analysis (0.2 and 1 Mb, respectively) ([@b17-mmr-22-02-1269],[@b27-mmr-22-02-1269]). In the present study, the resolution for CNV detection was set at 1 Mb, because: i) It is generally thought that CNVs \>10 Mb are directly associated with SM, 10 Mb \> CNVs \> 2 Mb recommend to reference the CNV database ([@b31-mmr-22-02-1269],[@b32-mmr-22-02-1269]); ii) the majority of copy-number polymorphisms are \<50 kb ([@b33-mmr-22-02-1269]); and iii) the purpose of present method was to define cost-effective approach for clinical settings in the spontaneous abortions analysis (\$100 per sample; 0.25X coverage). A total 437 SM samples were initially screened in a retrospective study, and the detection rates were in accordance with those of array CGH, with the exception of six CNVs \<1 Mb that were nonpathogenic repeats. In addition, the present method unambiguously detected aneuploidies, CNVs, and mosaicisms in SM samples, as well as CAs involving several chromosomes. Among the 964 samples analyzed prospectively, 341 aneuploidies were detected, the most common being T16, T22, T15, T21 and T13. Monosomy X was the most prevalent, which was in agreement with the findings of previous studies ([@b34-mmr-22-02-1269],[@b35-mmr-22-02-1269]). Previous studies indicated that T16, T22, and T15 trisomy in SM samples were associated with high probabilities of fetal death and anomalies, preterm delivery, and intrauterine growth retardation ([@b36-mmr-22-02-1269]). T21, T13 and monosomy X are often seen in SM during the first trimester ([@b37-mmr-22-02-1269]). Only a small portion of such fetuses survive to metaphase and advanced-stage pregnancy. If born, congenital malformations, such as Down\'s syndrome, Edward\'s syndrome and Turner\'s syndrome, may manifest ([@b30-mmr-22-02-1269]). Aneuploidy of chromosomes 1 and 19 is relatively rare ([@b3-mmr-22-02-1269],[@b38-mmr-22-02-1269],[@b39-mmr-22-02-1269]). In the present study, one case of tetrasomy 21 was detected. According to the small number of reported cases, tetrasomy 21 is extremely rare in constitutionally normal patients but is seen frequently in patients with acute megakaryoblastic leukemia ([@b40-mmr-22-02-1269]). It was reported that tetrasomy 21 has an association with physical features consistent with Down\'s syndrome ([@b42-mmr-22-02-1269]). However, of the 195 cases of CNVs in the present study, most were not associated with any pathological disease, with the exception of one case associated with WHS, one with DGS, and another associated with both PW and AS. WHS, DGS and PW or AS can affect some pregnancies, ultimately causing neonatal defects, such as developmental delays, skeletal anomalies, as well as cardiac, neurological and endocrinal abnormalities ([@b43-mmr-22-02-1269]--[@b45-mmr-22-02-1269]).

Neither array CGH nor low-coverage NGS can detect polyploidy. Therefore, supplementary STR profiling was performed, which allowed the identification of nine polyploidy cases in female euploidy and sex CA confirmatory tests. Although rare, polyploidy can cause miscarriage ([@b45-mmr-22-02-1269],[@b46-mmr-22-02-1269]). Altogether, these validation results suggested that comprehensive experimental results could be achieved by combining STR profiling with the NGS method described in the present study method, as a reliable and accurate approach for the diagnosis CAs associated with miscarriage.

In conclusion, CAs are the most common causes of abortion in SM, with trisomy being the most frequent, followed by CNVs and mosaicisms. In the present study, 565 samples were normal diploids. Early studies have reported that if the cytogenetics were normal, there was an increased risk of the next pregnancy failing ([@b47-mmr-22-02-1269],[@b48-mmr-22-02-1269]). There are many other causes of SM aside from genetic factors, such as maternal thrombophilic disorders, immune dysfunction and various endocrine dysregulation ([@b49-mmr-22-02-1269],[@b50-mmr-22-02-1269]). Due to the complexity of SM, studies with larger sample numbers and a variety of detection methods are needed to improve the diagnostic accuracy of spontaneous abortions.
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###### 

Diagnostic performance of NGS and identification of chromosomal abnormalities in 437 spontaneous miscarriage samples.

                        Sample size, n          
  --------------------- ---------------- ------ --------
  Trisomy               156              156    100.0
  Monosomy                34               34   100.0
  Multiple aneusomies     5                5    100.0
  Mosaicism               9                9    100.0
  CNVs                    68               74     91.9
  Euploidy              165              159    /
  Total                 437              437    /

NGS, next-generation sequencing; CGH, comparative genomic hybridization; CF, comparative fraction; CNVs, copy number variants.
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